Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketalar for Post-Mastectomy Chronic Pain Prevention
NCT00129597Phase 4
Key facts
- Status
- Unknown
- Start
- Dec 2004
- Countries
- 1
- Sponsor
- Hospices Civils de Lyon
- Modality
- Small Molecules
- Drugs
- ketamine
- Conditions
- chronic pain
01
Overview
Phase 4, randomised, double-blind trial of ketamine in chronic pain, sponsored by Hospices Civils de Lyon. Primary endpoint: Pain Intensity 3 Months After Mastectomy. Status: unknown.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adult patients (18-80) undergoing mastectomy for breast cancer, excluding those with ASA class 3 or higher, organ failure, ketamine allergy, psychiatric disorders, or pre-existing chronic pain treatment.
04
Endpoints
Primary
Pain Intensity 3 Months After Mastectomy
Secondary
Pain Intensity 1 Month After Mastectomy
Beyond the preview
Go deeper on NCT00129597.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129597.